Results 1 to 10 of about 66,822 (310)
Endocrinology and Metabolism Clinics of North America, 2003 Osteoporosis is the result of bone loss due to an imbalance in bone turnover such that bone resorption exceeds bone formation. Bisphosphonates are potent inhibitors of osteoclast activity that reduce bone turnover and re-establish the balance between bone resorption and formation. In clinical studies, several bisphosphonates prevent bone loss, preserve
Julie T, Lin, Joseph M, Lane
openaire +7 more sources
Frontiers in Medicine, 2021 Bisphosphonate has great potential in KOA therapy, but whether the anti-resorption mechanism of bisphosphonate aggravates sclerosis of subchondral bone remains unclear.
Mingyang Li +7 more
doaj +1 more source
Annals of the New York Academy of Sciences, 2006 Abstract: Bisphosphonates belong to a class of compounds similar to pyrophosphate. In these compounds the oxygen atom of the pyrophosphate is replaced by a carbon atom resulting in a P‐C‐P bond. They exert a potent inhibitory effect on osteoclasts and are therefore potent antiresorptive agents. They reduce bone turnover, increase bone mineral density,
Lambrinoudaki, I. +2 more
+7 more sources
Risk factors for medication-related osteonecrosis of the jaw and salivary IL-6 IN cancer patients
Brazilian Journal of Otorhinolaryngology, 2022 Introduction: Medication-related osteonecrosis of the jaws is a severe complication of the use of antiresorptive and antiangiogenic therapy, with limited treatment options and great impact on patient’s quality pf life.
Aristilia Pricila Tahara Kemp +7 more
doaj +1 more source
How much we know about bisphosphonate lesions [PDF]
Acta Stomatologica Naissi, 2016 Introduction: Bisphosphonate drugs are used in the treatment of the osteoporosis and malignant processes in the bone tissue. As a result of this use bisphosphonate lesions are formed in bone tissue and oral mucosis, which representing a remarkable ...
Pešić Zoran +2 more
doaj +1 more source
Bisphosphonate nephrotoxicity [PDF]
Kidney International, 2008 Bisphosphonates are valuable agents for the treatment of post-menopausal osteoporosis (PMO), hypercalcemia of malignancy, and osteolytic bone metastases. Oral bisphosphonates are used mainly to treat PMO and are not associated with significant nephrotoxicity.
Perazella, Mark A., Markowitz, Glen S.
openaire +2 more sources
Medical and Health Science Journal, 2020 INTRODUCTION Osteogenesis imperfecta (OI) or brittle bone disease is a connective tissue formation disorder that is generally characterized by bone fragility, osteopenia, blue sclera, dentinogenesis imperfecta (DI), and hearing loss.
Baskoro Kusumo Riswanto +1 more
doaj +1 more source
Bone Quality and Fractures in Women With Osteoporosis Treated With Bisphosphonates for 1 to 14 Years
JBMR Plus, 2021 Oral bisphosphonates are the primary medication for osteoporosis, but concerns exist regarding potential bone‐quality changes or low‐energy fractures.
Hartmut H Malluche +5 more
doaj +1 more source
Topical zoledronic acid decreases micromotion induced bone resorption in a sheep arthroplasty model
BMC Musculoskeletal Disorders, 2017 Background Initial micromotion of a total hip replacement is associated with aseptic loosening. The use of bisphosphonates could be one way to reduce peri-implant bone resorption induced by micromotion.
Thomas Jakobsen +5 more
doaj +1 more source
Drugs in Context, 2020 Background: On stopping bisphosphonate treatment, bone resorption may increase before evidence of a decrease in bone density. Offset of bisphosphonate effect may therefore be monitored by measuring C-terminal telopeptide (CTX) following long-term ...
Louise Statham +2 more
doaj +1 more source